市場調查報告書

全球便秘治療市場:成長,趨勢,及預測(2020年∼2025年)

Constipation Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921897
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球便秘治療市場:成長,趨勢,及預測(2020年∼2025年) Constipation Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

全球便秘治療市場,由於老年人口的增加和飲食習慣的變化,IBS-C,OIC,慢性便秘的高盛行率,最新的藥物、治療手段的開發等要素預計急速成長。尤其是,大腸激躁症(IBS)影響全球人口最大7%∼18%,由於盛行率的增加成為該市場整體原動力。市場有各種適合IBS的藥,在緩和便秘方面也有比安慰劑出色的新藥物治療。可是,沒有處理IBS-C的單一方法。進行飲食、運動、壓力管理、投藥的變更等各種治療方法,影響該市場整體成長。

本報告提供全球便秘治療市場的相關調查,市場機會和趨勢,成長及阻礙因素,各治療藥、疾病、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 老年人口的增加和飲食習慣的變化
    • IBS-C,OIC及慢性便秘的高盛行率
    • 最新的藥物及治療手段的開發
  • 市場阻礙因素
    • 對店面銷售(OTC)藥的大半的依賴度增加
  • 波特的五力分析

第5章 市場區隔

  • 各治療藥物
    • 瀉藥
    • 氯離子通道活化劑
    • 末梢性類鴉片物質受體拮抗劑
    • GC-C受體激動劑
    • 5-HT4受體激動劑
  • 各疾病類型
    • 慢性特發性便秘(CIC)
    • 便秘伴隨的大腸激躁症(IBS-C)
    • 類鴉片物質誘發性便秘(OIC)
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • 武田藥品工業株式會社
    • Synergy Pharmaceuticals, Inc.
    • Ironwood Pharmaceuticals, Inc.
    • Salix Pharmaceuticals
    • Abbott Laboratories
    • AstraZeneca
    • Cosmo Pharmaceuticals NV
    • Sanofi
    • Bayer AG

第7章 市場機會及今後趨勢

目錄
Product Code: 67441

Market Overview

The constipation treatment market will show rapid growth due to factors such as increasing geriatric population and changing dietary habits, high prevalence of IBS-C, OIC and chronic constipation and the development of the latest drugs and treatment procedures.

The irritable bowel syndrome (IBS) is found to be a chronic, recurring, and remitting functional disorder of the gastrointestinal tract that causes abdominal pain, distention, and changes in bowel habits. Irritable bowel syndrome (IBS) is found affecting up to 7%-18% of the population worldwide and therefore its prevalence is increasing that is driving the overall market. Although there are several drugs for IBS in the market that are effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed.

There are also newer pharmacological treatments being available for constipation that is superior to placebo in relieving constipation. But there is no single approach to treat IBS-C. Often, people use a mix of therapies to get relief. They can include changes in diet, exercise, stress management, and medication. Hence all these factors are associated with the increase in the overall growth of the market.

Scope of the Report

As per the scope of the report, constipation is a common medical condition that affects the normal life of an individual, and prolonged constipation could be a symptom of more severe diseases and disorders. It is estimated to affect every one individual once in a lifetime. Constipation may be occasional which lasts for a few weeks or maybe chronic which lasts for a longer period and is recurrent. Therefore it may be associated with other conditions such as irritable bowel syndrome or opioid consumption also.

Key Market Trends

Laxatives are Expected to Dominate the Constipation Market During the Forecast Period

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu-opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. And the laxatives are a type of medicine that can treat constipation. They're often used if lifestyle changes, such as increasing the amount of fiber in your diet, drinking plenty of fluid and taking regular exercise, have not helped. Therefore over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment.

North America is Found to be the Largest Growing Region in the Constipation Market

North America is found to be the largest growing region of the market, and it is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. Furthermore, the U.S. holds the largest market share in the North America region owing to factors such as the presence of a large number of market players manufacturing medications for constipation. And Canada is expected to show the fastest growth in North America which is driven by the overall increasing demand for diagnostic and treatment methods.

Asia Pacific is also expected to be the fastest-growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of GI diseases.

Competitive Landscape

The heavy investments are being made by manufacturers towards the development of novel therapeutic drugs for constipation and are expected to fortify the global market. These ardent efforts by the manufacturers of therapeutic drugs for the treatment of constipation have aided the growth of the global market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Geriatric Population and Changing Dietary Habits
    • 4.2.2 High Prevalence of IBS-C, OIC and Chronic Constipation
    • 4.2.3 Development of Latest Drugs and Treatment Procedures
  • 4.3 Market Restraints
    • 4.3.1 Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutic
    • 5.1.1 Laxatives
    • 5.1.2 Chloride channel activators
    • 5.1.3 Peripherally Acting Mu-Opioid Receptor Antagonists
    • 5.1.4 GC-C Agonists
    • 5.1.5 5-HT4 Receptor Agonists
  • 5.2 By Disease Type
    • 5.2.1 Chronic idiopathic constipation (CIC)
    • 5.2.2 Irritable bowel syndrome with constipation (IBS-C)
    • 5.2.3 Opioid-induced constipation (OIC)
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Takeda Pharmaceutical Company Ltd
    • 6.1.2 Synergy Pharmaceuticals, Inc.
    • 6.1.3 Ironwood Pharmaceuticals, Inc.
    • 6.1.4 Salix Pharmaceuticals
    • 6.1.5 Abbott Laboratories
    • 6.1.6 AstraZeneca
    • 6.1.7 Cosmo Pharmaceuticals NV
    • 6.1.8 Sanofi
    • 6.1.9 Bayer AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS